Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Lourdes Rodriguez Fernández-Freire"'
Autor:
Esteban Daudén, Gregorio Carretero, Raquel Rivera, Carlos Ferrándiz, Mar Llamas-Velasco, Pablo de la Cueva, Isabel Belinchón, Francisco José Gómez-García, Enrique Herrera-Acosta, Diana Patricia Ruiz-Genao, Marta Ferrán-Farrés, Mercè Alsina, Ofelia Baniandrés-Rodríguez, José Luis Sánchez-Carazo, Antonio Sahuquillo-Torralba, Lourdes Rodriguez Fernández-Freire, Jaime Vilar-Alejo, Carmen García-Donoso, José Manuel Carrascosa, Enrique Herrera-Ceballos, José Luis López-Estebaranz, Rafael Botella-Estrada, Eva Segovia-Muñoz, Miguel Angel Descalzo, Ignacio García-Doval, Ferrán Ballescá, Fran J. Gómez-García, Rafael Jiménez, Marta Ferrán Farrés, Ofelia Baniandrés, Lula Nieto, Conrad Pujol Marco, Lourdes Rodríguez Fernández-Freire, Almudena Mateu Puchades, Ángeles Flórez Menéndez, Laura Salgado, Beatriz González Sixto, Noemí Eiris, Miguel Ángel Descalzo Gallego, Marina de Vega Martínez
Publikováno v:
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
instname
Background: Registry studies broadly describing the safety of systemic drugs in psoriasis are needed. Objective: To describe the safety findings of the systemic drugs acitretin, adalimumab, apremilast, cyclosporine, etanercept, infliximab, methotrexa
Autor:
Elena del Alcázar, Anna López-Ferrer, Álvaro Martínez-Doménech, Marc Julià, Ricardo Ruiz-Villaverde, Lourdes Rodríguez Fernández-Freire, Jaime Notario, Mar Llamas-Velasco, Marta Ferran, José Manuel Carrascosa
Publikováno v:
Journal of Dermatological Treatment, Vol 33, Iss 6, Pp 2878-2880 (2022)
Externí odkaz:
https://doaj.org/article/b549d7381391484298ade3556aa7a932
Autor:
Ricardo Ruiz-Villaverde, Lourdes Rodriguez Fernandez-Freire, Pilar Font-Ugalde, Manuel Galan-Gutierrez
Publikováno v:
Journal of Clinical Medicine, Vol 11, Iss 17, p 5098 (2022)
Tildrakizumab (TIL) binds selectively to the p19 subunit of interleukin 23. Its introduction has managed to increase the levels of efficacy, safety (improving that previously presented by the anti-IL-12/23 class) and survival. Retrospective analysis
Externí odkaz:
https://doaj.org/article/25a586d2530243e1bfd591771b609b1a
Autor:
Juan Ortiz-Álvarez, Jose Antonio Lebron-Martin, Lourdes Rodriguez Fernandez-Freire, Teresa Zulueta-Dorado, Jose Salvador Garcia-Morillo
Publikováno v:
European Journal of Case Reports in Internal Medicine (2021)
Dermal fillers are applied using a minimally invasive technique with a good safety profile. However, they can have side effects. We present the case of a patient who, 2 months after undergoing polycaprolactone (Ellansé®) injections, developed nodul
Externí odkaz:
https://doaj.org/article/0264d445da8f46289fe9e20a5c99ea71
Autor:
Lluís Puig, Lourdes Rodríguez Fernández-Freire, Ramón Burgos-Pol, Ismael Gomez, Carmen Peral, Susana Gomez, Francisco José Rebollo Laserna
Publikováno v:
Dermatology and Therapy, Vol 9, Iss 3, Pp 479-496 (2019)
Abstract Introduction Etanercept (ETN), a highly effective biological agent for the treatment of psoriasis (PSO) and psoriatic arthritis (PsA), is widely used in Spain. However, evidence of its economic impact is limited, indicating the need for a sy
Externí odkaz:
https://doaj.org/article/f0a79d22ccaa426c84f56b29812a1ad3